
11 Jan 2019 Research
Myelofibrosis: Finding new ways to treat patients
Myelofibrosis is a fatal bone marrow cancer. The disease is caused by excessive secretion of factors by cancerous platelet-producing cells called megakaryocytes. These secretions cause the replacement of normal bone marrow tissue with fibrous scar tissue.
Dr Chen’s team can successfully recreate this pathological bone marrow environment in the laboratory, and their preliminary research data shows that reduced levels of a protein complex called FANCcore leads to more myelofibrosis.
Dr Chen’s team hypothesise that loss of the protein complex FANCcore increases the growth of myelfibrosis by altering megakaryocytes. Dr Chen uses both human tissue cultures and mouse models to examine the cellular and molecular changes to megakaryocytes following the absence of the FANCcore complex and to understand how these changes cause myelofibrosis.
The team hopes that by focusing on the role of FANCcore in megakaryocyte biology, they can reveal new ways to treat myelofibrosis.
Related posts
16 November 2022
Leukaemia UK and Leukaemia Care urge benefits to be raised in line with inflation
Leukaemia UK and Leukaemia Care have written to the Chancellor to highlight the additional financial pressures faced by blood cancer patients and their families, ahead of the Autumn Statement this…
19 December 2023
Beloved actor who beat leukaemia now fronting charity TV ad to help raise vital funds
83-year-old actor Richard Tate will appear on screens from 26th December onwards to support Leukaemia UK’s call for legacy pledges (otherwise known as gifts in Wills), after surviving leukaemia thanks…
3 February 2022
Leukaemia UK awarded Christmas Grant to support life-saving research
Leukaemia UK are delighted to have been awarded a special Christmas Grant from Kusuma Trust UK.
4 April 2023
£200 grants for people affected by leukaemia once again available
Leukaemia UK and Leukaemia Care have this month relaunched the ‘Cost of Living Fund’, providing financial grants of £200 to patients with leukaemia, myelodysplastic syndrome (MDS) or myeloproliferative neoplasms (MPNs),…